Fulcrum Therapeutics (FULC) director awarded options on 32,000 shares

Rhea-AI Filing Summary

Fulcrum Therapeutics director Rachel K. King received a grant of stock options covering 32,000 shares of common stock. These options give her the right to buy shares at an exercise price of $3.66 per share, aligning part of her compensation with the company’s future performance.

The option grant is scheduled to vest in full on the first anniversary of the June 30, 2026 grant date, or earlier immediately before the first annual stockholder meeting after that date, as long as she continues in service. After this grant, she holds options for 32,000 underlying shares that expire on June 29, 2036. This is a compensation-related award rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider King Rachel K.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	32,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 32,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 32,000 shares Exercise price: $3.66 per share Post-grant options held: 32,000 shares +2 more

5 metrics

Option grant size 32,000 shares Stock Option (right to buy) granted June 30, 2026

Exercise price $3.66 per share Conversion or exercise price of stock options

Post-grant options held 32,000 shares Total underlying shares following transaction

Option expiration June 29, 2036 Expiration date of stock option grant

Vesting schedule 100% after ~1 year Vests on first anniversary or earlier before first annual meeting

Key Terms

Stock Option (right to buy), grant/award acquisition, conversion or exercise price, vesting, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

conversion or exercise price financial

"conversion_or_exercise_price: 3.6600"

vesting financial

"is scheduled to vest with respect to all shares"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: 2036-06-29T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 04:31 PM Accepted by SEC EDGAR 07/02/2026 - 04:30 PM Learn about SEC filing dates

FAQ

What did Fulcrum Therapeutics (FULC) director Rachel K. King report in this Form 4?

Rachel K. King reported receiving a stock option grant for 32,000 shares of Fulcrum Therapeutics common stock. The options are a form of equity compensation and do not represent an open-market purchase or sale of existing shares.

How many Fulcrum Therapeutics (FULC) shares are covered by the new option grant?

The new option grant covers 32,000 underlying shares of Fulcrum Therapeutics common stock. These options give Rachel K. King the right to buy those shares in the future at a fixed exercise price if the options vest.

What is the exercise price and expiration date of Rachel K. King’s Fulcrum options?

The stock options have an exercise price of $3.66 per share and are scheduled to expire on June 29, 2036. This defines both the cost to exercise and the latest date they can be used.

When do Rachel K. King’s Fulcrum Therapeutics options vest?

The options are scheduled to vest with respect to all 32,000 shares on the first anniversary of the June 30, 2026 grant date, or earlier immediately before the first annual stockholder meeting after that date, subject to continued service.

Does this Form 4 show Rachel K. King buying or selling Fulcrum stock on the market?

No. The Form 4 shows a grant of stock options as compensation, not an open-market purchase or sale. It reflects an award that may be exercised later, rather than immediate trading in Fulcrum shares.

How many options does Rachel K. King hold after this Fulcrum option grant?

After this transaction, Rachel K. King holds options over 32,000 underlying shares of Fulcrum Therapeutics common stock. This reflects her position following the reported grant on June 30, 2026.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

King Rachel K.

(Last) (First) (Middle)

C/O FULCRUM THERAPEUTICS, INC.

26 LANDSDOWNE STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Fulcrum Therapeutics, Inc. [ FULC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.66	06/30/2026		A		32,000		(1)	06/29/2036	Common Stock	32,000	$0.00	32,000	D

Explanation of Responses:

1. This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

	/s/ Alan Musso, as attorney-in-fact for Rachel King	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)